NCT05824975 2024-11-25A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)GI Innovation, Inc.Phase 1/2 Recruiting358 enrolled
NCT03678883 2024-11-079-ING-41 in Patients with Advanced CancersActuate Therapeutics Inc.Phase 2 Active not recruiting350 enrolled
NCT01375699 2019-08-26Doxorubicin With or Without Sildenafil, With Analysis of Cardiac MarkersVirginia Commonwealth UniversityPhase 1 Completed26 enrolled
NCT00098579 2013-03-19Doxorubicin Hydrochloride and Alvocidib in Treating Patients With Metastatic or Recurrent Sarcoma That Cannot Be Removed By SurgeryNational Cancer Institute (NCI)Phase 1 Completed36 enrolled